Stock Track | Tigermed Plunges Despite Solid Q2 Results Amid Investor Disappointment

Stock Track08-29

Shares of Tigermed Consulting Co., Ltd. (03347.HK), a leading China-based clinical research services provider, plummeted as much as 7.37% in intraday trading on Wednesday, despite the company reporting solid second-quarter results.

For the quarter ended June 30, Tigermed's total revenue rose 2.3% quarter-over-quarter to RMB 1.698 billion, while gross profit increased 12.2% to RMB 705 million. The company also reported an 11.3% increase in net profit attributable to shareholders, reaching RMB 337 million.

However, the strong financial results seem to have failed to meet investor expectations, as Tigermed's stock price faced heavy selling pressure. Analysts suggest that the market may have been anticipating an even stronger performance, given the company's robust growth trajectory and the increasing demand for clinical research services in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156132637?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-29 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156132637","market":"hk","top_or_hot":-1,"title":"Stock Track | Tigermed Plunges Despite Solid Q2 Results Amid Investor Disappointment","media":"Stock Track","content":"<p>Shares of Tigermed Consulting Co., Ltd. (03347.HK), a leading China-based clinical research services provider, plummeted as much as 7.37% in intraday trading on Wednesday, despite the company reporting solid second-quarter results.</p>\n\n<p>For the quarter ended June 30, Tigermed's total revenue rose 2.3% quarter-over-quarter to RMB 1.698 billion, while gross profit increased 12.2% to RMB 705 million. The company also reported an 11.3% increase in net profit attributable to shareholders, reaching RMB 337 million.</p>\n\n<p>However, the strong financial results seem to have failed to meet investor expectations, as Tigermed's stock price faced heavy selling pressure. Analysts suggest that the market may have been anticipating an even stronger performance, given the company's robust growth trajectory and the increasing demand for clinical research services in China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tigermed Plunges Despite Solid Q2 Results Amid Investor Disappointment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tigermed Plunges Despite Solid Q2 Results Amid Investor Disappointment\n</h2>\n\n<h4 class=\"meta\">\n\n2024-08-29 16:28 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Tigermed Consulting Co., Ltd. (03347.HK), a leading China-based clinical research services provider, plummeted as much as 7.37% in intraday trading on Wednesday, despite the company ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03347","symbol_name":"泰格医药","start_time":0,"source_url":"","article_id":"1156132637","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156132637","pubTimestamp":1724920121,"sourceInfo":null,"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Tigermed Consulting Co., Ltd. , a leading China-based clinical research services provider, plummeted as much as 7.37% in intraday trading on Wednesday, despite the company reporting solid second-quarter results.For the quarter ended June 30, Tigermed's total revenue rose 2.3% quarter-over-quarter to RMB 1.698 billion, while gross profit increased 12.2% to RMB 705 million. The company also reported an 11.3% increase in net profit attributable to shareholders, reaching RMB 337 million.Ho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03347":"泰格医药"},"translate_title":"尽管第二季度业绩稳健，但投资者失望，泰格医药股价仍暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1},"content_text":"Shares of Tigermed Consulting Co., Ltd. (03347.HK), a leading China-based clinical research services provider, plummeted as much as 7.37% in intraday trading on Wednesday, despite the company reporting solid second-quarter results.\nFor the quarter ended June 30, Tigermed's total revenue rose 2.3% quarter-over-quarter to RMB 1.698 billion, while gross profit increased 12.2% to RMB 705 million. The company also reported an 11.3% increase in net profit attributable to shareholders, reaching RMB 337 million.\nHowever, the strong financial results seem to have failed to meet investor expectations, as Tigermed's stock price faced heavy selling pressure. Analysts suggest that the market may have been anticipating an even stronger performance, given the company's robust growth trajectory and the increasing demand for clinical research services in China.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156132637"}